| 000 | 01391 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250514034920.0 | ||
| 264 | 0 | _c20021213 | |
| 008 | 200212s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1093/annonc/mdf142 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHejna, M | |
| 245 | 0 | 0 |
_aThe clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMay 2002 |
||
| 300 |
_a653-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aOctreotide _xadverse effects |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xadverse effects |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aSomatostatin _xadverse effects |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSchmidinger, M | |
| 700 | 1 | _aRaderer, M | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 13 _gno. 5 _gp. 653-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdf142 _zAvailable from publisher's website |
| 999 |
_c11970632 _d11970632 |
||